BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 8838483)

  • 21. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
    Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
    Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
    Prasad RN; Koh SC; Viegas OA; Ratnam SS
    Clin Appl Thromb Hemost; 1999 Jan; 5(1):60-70. PubMed ID: 10725985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene.
    Fuchs N; Düsterberg B; Weber-Diehl F; Mühe B
    Contraception; 1995 Jun; 51(6):335-9. PubMed ID: 7554972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
    Basdevant A; Conard J; Pelissier C; Guyene TT; Lapousterle C; Mayer M; Guy-Grand B; Degrelle H
    Contraception; 1993 Sep; 48(3):193-204. PubMed ID: 8222650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
    Jespersen J; Petersen KR; Skouby SO
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):396-403. PubMed ID: 2196812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects on hemostasis of oral contraceptives containing desogestrel.
    Stubblefield PG
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1047-52. PubMed ID: 8447359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haemostatic changes and the oral contraceptive pill.
    Norris LA; Bonnar J
    Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):545-64. PubMed ID: 9488791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women.
    Paoletti AM; Orrù M; Floris S; Mannias M; Vacca AM; Ajossa S; Guerriero S; Melis GB
    Contraception; 2000 Apr; 61(4):259-63. PubMed ID: 10899481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
    Ferreira AC; Montes MB; Franceschini SA; Toloi MR
    Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
    Spellacy WN; Tsibris JC; Hunter-Bonner DL; Smalling S; Chez RA; Angel JL; O'Brien WF
    Contraception; 1992 Jun; 45(6):533-9. PubMed ID: 1617962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gestodene-containing contraceptives.
    Kuhl H; Jung-Hoffmann C; Wiegratz I
    Clin Obstet Gynecol; 1995 Dec; 38(4):829-40. PubMed ID: 8616979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Desogestrel versus gestodene in oral contraceptives: influence on the clinical and histomorphological features of benign breast disease.
    Di Lieto A; De Rosa G; Albano G; Pagnano AM; Campanile M; Terracciano L; Pontillo M; Cimmino E; Covelli A; Paladini A
    Eur J Obstet Gynecol Reprod Biol; 1994 May; 55(1):71-83. PubMed ID: 7958144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
    Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.